Xenon Pharmaceut Stock Price, News & Analysis

Xenon Pharmaceuticals announced equity inducement grants to seven new non-officer employees, totaling 53,550 share options. The options, approved by the Compensation Committee with an effective date of May 29, 2025, have an exercise price of $29.04 per share, matching the closing price on the grant date. These grants vest over four years, with 25% vesting after one year and the remaining vesting monthly over three years. The options have a 10-year term and are subject to the 2025 Inducement Equity Incentive Plan. Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression, with their lead candidate azetukalner, a Kv7 potassium channel opener, in late-stage clinical development.

Xenon Pharmaceuticals (Nasdaq: XENE) announced its participation in the upcoming 2025 RBC Capital Markets Global Healthcare Conference in New York. CEO Ian Mortimer will present a fireside chat on Wednesday, May 21, 2025, from 10:30-10:55 AM ET. The presentation will be available via webcast on Xenon's website.

Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.

Xenon Pharmaceuticals (XENE) reported Q1 2025 financial results and pipeline updates. The company's lead drug azetukalner is progressing in multiple Phase 3 trials. The X-TOLE2 focal onset seizures study is expected to complete recruitment soon, with topline data anticipated in early 2026. Two additional Phase 3 trials - X-NOVA3 for major depressive disorder (MDD) and a study for bipolar depression - are set to begin mid-year. The company initiated a Phase 1 study for XEN1120, a new Kv7 channel opener, and plans to file an IND for XEN1701, their Nav1.7 candidate, in Q3 2025. Financially, Xenon reported $691.1M in cash and equivalents as of March 31, 2025, with a net loss of $65.0M for Q1. Revenue was $7.5M, while R&D expenses increased to $61.2M. The company expects current cash to fund operations into 2027.

Xenon Pharmaceuticals (Nasdaq: XENE) has scheduled to release its first quarter 2025 financial results and provide a business update after U.S. market close on Monday, May 12, 2025. The company will host a conference call at 4:30 pm Eastern Time on the same day.

Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.

Xenon Pharmaceuticals (NASDAQ: XENE) has announced equity inducement grants to four new non-officer employees, consisting of 78,600 share options and 1,800 performance share units (PSUs). The grants, effective May 2, 2025, were approved by the Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $38.28 per common share, vesting over four years with a 10-year term. The PSUs will vest based on achieving predefined milestone-based objectives over approximately three years.

Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead product, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.

Xenon Pharmaceuticals (XENE) has announced multiple presentations at the upcoming American Academy of Neurology Annual Meeting (AAN 2025) in San Diego. The company will showcase three key posters, highlighting significant progress in their epilepsy treatment research.

The main focus is on azetukalner, their novel Kv7 potassium channel opener, featuring 36-month long-term data from the ongoing X-TOLE open-label extension study in patients with focal onset seizures (FOS). The data demonstrates sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and a consistent safety profile.

Additional presentations include an exploratory analysis showing reduced seizure frequency across four focal seizure subtypes, and patient survey findings regarding mental health and comorbidity burdens of FOS. The presentations will take place between April 5-9, 2025, with Xenon also hosting booth #1110 in the Exhibit Hall.

Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced its participation in the upcoming Stifel 2025 Virtual CNS Forum, scheduled for March 18-19, 2025. The company will deliver a fireside chat presentation, which will be accessible via live audio webcast on the 'Investors' section of Xenon's website.

Xenon specializes in developing ion channel product portfolio targeting areas with high unmet medical needs, particularly epilepsy and depression. Their leading product, Azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications. This compound represents the most advanced, clinically validated potassium channel modulator in development.

Xenon Pharmaceuticals (XENE) has provided its Q4 and full year 2024 financial results and business update. The company's lead drug candidate azetukalner is advancing in multiple Phase 3 trials, with topline data for focal onset seizures expected in H2 2025. The company is expanding its neuropsychiatric programs, with the first of three Phase 3 trials for major depressive disorder underway and plans to initiate bipolar depression studies mid-year.

Financial highlights include: Cash position of $754.4 million as of December 31, 2024, expected to fund operations into 2027. R&D expenses increased to $210.4 million for 2024, up from $167.5 million in 2023. Net loss widened to $234.3 million in 2024 compared to $182.4 million in 2023.

The company announced CFO Sherry Aulin will step down on June 30, 2025. Additionally, Xenon's collaboration with Neurocrine Biosciences achieved a milestone with the initiation of a Phase 1 study of their Nav1.2/Nav1.6 inhibitor, triggering a $7.5 million payment.

Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced its participation in the 45th Annual TD Cowen Healthcare Conference scheduled for March 3-5, 2025, in Boston, MA.

The company will provide a live audio webcast of their presentation, which will be accessible through the 'Investors' section of Xenon's website, with a replay option available post-event.

Xenon specializes in developing ion channel products targeting epilepsy and depression. Their leading product, azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications.